Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Evolution of atenolol kinetics when hypothyroidism is corrected

  • 23 Accesses

Summary

A single oral dose of atenolol 100 mg was given to 7 hypothyroid patients (4 F, 3 M), before and after correction of hypothyroidism, mean delay 3.5 months (2 to 6.5 months).

There was no change in the elimination parameters of atenolol, but the maximal plasma atenolol concentration was increased (1.66 to 7.37 mg·l−1) as was the AUC (14.9 to 52.1 mg·l−1·h) when the hypothyroidism had been treated. Only one patient differed: he had had a supra-selective vagotomy, and had similar curves before and after treatment of the hypothyroidism, both being similar to the plasma concentration curves found in the other patients after correction of the hypothyroidism.

The results suggest an increase in the bioavailability of atenolol when hypothyroidism is corrected. The findings in the patient with vagotomy suggest that the decreased bioavailability during hypothyroidism might be related to changes in intestinal pH. Further studies are needed of the impact of hypothyroidism on gastric and pancreatic or biliary function and its consequences for drug absorption, and drug pharmacokinetics.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Shenfield GM (1981) Influence of thryoid dysfunction on drug pharmacokinetics. Clin Pharmacokinet 6: 275–97

  2. 2.

    Feely J (1983) Clinical pharmacokinetics of beta-adrenoceptor blocking drugs in thyroid disease. Clin Pharmacokinet 8: 1–16

  3. 3.

    Bell JM, Russell CJ, Nelson JK, Kelly JC, McDevitt DG (1977) Studies of the effect of thyroid dysfunction on the elimination of β-adrenoceptor blocking drugs. Br J Clin Pharmacol 4: 79–82

  4. 4.

    Flouvat B, Bazin M, Lucsko M, Roux A, Guedon J (1978) Dosage spectrofluorimétrique dans les milieux biologiques d'un nouveau beta-bloquant, l'Atenolol. Application à son étude pharmacocinétique. Ann Biol Clin 36: 339–346

  5. 5.

    d'Athis Ph (1988) Programme Triomphe®: Traitement Interactif Ordonné des Modèles Pharmacologiques Elémentaires. Département d'Informatique Médicale, Faculté de Médecine, CHUR Dijon, France

  6. 6.

    Gibaldi P (1977) Biopharmaceutics and Clinical Pharmacokinetics, 2nd ed. Lea and Febiger, Philadelphia

  7. 7.

    Feely J, Stevenson IH, Crooks J (1981) altered plasma protein binding of drugs in thyroid disease. Clin Pharmacokinet 6: 298–305

  8. 8.

    Middleton WRJ (1971) Thyroid hormones and the gut. Gut 12: 172–177

  9. 9.

    Nimmo WS (1976) Drugs, diseases, and altered gastricemptying. Clin Pharmacokinet 1: 189–203

  10. 10.

    Yamaghishi F, Iijima K, Komiya I, Yamada T, Chiba S (1985) Effects of thyrotropin-releasing hormone on pancreatic exocrine secretion in the dog. Arch Int Pharmacodyn Ther 274: 159–165

  11. 11.

    Kato Y, Kanno T (1983) Thyrotropin releasing hormone injected intracerebroventricularly in the rat stimulates exocrine pancreatic secretion via the vagus nerve. Reg Pep 7: 347–356

  12. 12.

    Gullo L, Labo G (1981) Thyrotropin-releasing hormone inhibitis pancreatic enzyme secretion in humans. Gastroenterology 80: 735–739

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Levesque, H., Richard, M.O., Fresel, J. et al. Evolution of atenolol kinetics when hypothyroidism is corrected. Eur J Clin Pharmacol 38, 185–188 (1990). https://doi.org/10.1007/BF00265982

Download citation

Key words

  • Atenolol
  • Hypothyroidism
  • Drug absorption
  • Pharmacokinetics